{"protocolSection":{"identificationModule":{"nctId":"NCT01243775","orgStudyIdInfo":{"id":"m601NSC10B"},"organization":{"fullName":"Chonnam National University Hospital","class":"OTHER"},"briefTitle":"BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC","officialTitle":"Phase II Trial of First Line Docetaxel and Oxaliplatin in Stage IV or Relapsed Non-Small Cell Lung Cancer","acronym":"BELOXAN"},"statusModule":{"statusVerifiedDate":"2015-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-11"},"primaryCompletionDateStruct":{"date":"2013-01","type":"ACTUAL"},"completionDateStruct":{"date":"2013-01","type":"ACTUAL"},"studyFirstSubmitDate":"2010-11-15","studyFirstSubmitQcDate":"2010-11-18","studyFirstPostDateStruct":{"date":"2010-11-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-07-19","resultsFirstSubmitQcDate":"2015-07-20","resultsFirstPostDateStruct":{"date":"2015-08-17","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-07-20","lastUpdatePostDateStruct":{"date":"2015-08-17","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Young-Chul Kim","investigatorTitle":"Professor","investigatorAffiliation":"Chonnam National University Hospital"},"leadSponsor":{"name":"Chonnam National University Hospital","class":"OTHER"},"collaborators":[{"name":"Chong Kun Dang Pharmaceutical","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Lung cancer is the leading cause of cancer death in Korea as well as in other countries. About 80% of lung cancer is non-small cell lung cancer(NSCLC). The majority of patients with NSCLC require cytotoxic chemotherapy in the course of their illness. Combination chemotherapy using third generation anticancer drugs (paclitaxel, docetaxel, gemcitabine) with platinums(cisplatin or carboplatin) reached a plateau in their efficacy. Oxaliplatin, another platinum being used for colorectal, gastric and pancreatic cancer has lower adverse effects such as nausea and nephrotoxicity. In this phase II trial, we will observe efficacy and safety of docetaxel and oxaliplatin for patients with NSCLC."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["NSCLC"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":33,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Belotaxel plus Belloxa","type":"EXPERIMENTAL","description":"Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)","interventionNames":["Drug: Belotaxel","Drug: Belloxa"]}],"interventions":[{"type":"DRUG","name":"Belotaxel","description":"60 mg/m2 3 weekly (day 1)","armGroupLabels":["Belotaxel plus Belloxa"],"otherNames":["Docetaxel"]},{"type":"DRUG","name":"Belloxa","description":"70 mg/m2 3 weekly (day 2)","armGroupLabels":["Belotaxel plus Belloxa"],"otherNames":["Oxaliplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Response Rate","description":"RECIST version 1.1","timeFrame":"6th week"}],"secondaryOutcomes":[{"measure":"Progression Free Survival","timeFrame":"2 years"},{"measure":"Overall Survival","timeFrame":"2 years"},{"measure":"Neutropenia Grade 3-4","description":"Toxicity (CECAE ver 4.0) and Safety","timeFrame":"2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stage IIIB/IV or Relapsed NSCLC\n* Age \\>= 18 years\n* At least one measurable lesion by RECIST (version 1.1)\n* ECOG PS 0, 1, 2\n* Hematologic profile\n\n  * Hgb \\> 8 g/dL, ANC \\>= 2,000/m3, Platelet \\>= 100,000/m3\n* Hepatic profile\n\n  * Total bilirubin \\<= 1.5 x upper normal value\n  * Transaminases \\<= 3 x upper normal value \\<= 5 x upper normal value in case of liver metastasis\n* Creatinine \\<= 1.5mg/dL\n* Patients should be recovered from toxicities of previous treatment.\n* Written informed consent by patient or surrogates\n\nExclusion Criteria:\n\n* Patients who had been previously treated with chemotherapy for NSCLC\n* Active infection requiring antibiotics treatment\n* Prior diagnosis of other malignancy except radically treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the uterine cervix\n* Peripheral neuropathy \\>= grade 2 by NCI CTCAE 4.0\n* Uncontrolled hypertension, Acute myocardial infarction within 6 months Unstable angina, Congestive heart failure \\>= NYHA grade 2 Uncontrolled significant arrhythmia\n* Patients who entered other clinical trials within 4 weeks\n* Pregnant or lactating women. women with child bearing age who are not willing to a contraceptive measure","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Young-Chul Kim, MD, PhD","affiliation":"Chonnam National University Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Chonnam National University Hwasun Hospital","city":"Hwasun","state":"Jeollanam-do","zip":"519-809","country":"South Korea","geoPoint":{"lat":35.06125,"lon":126.98746}}]},"referencesModule":{"references":[{"pmid":"26767047","type":"RESULT","citation":"Ban H, Kim KS, Oh IJ, Yoon SH, Lee B, Yu J, Kim S, Lee HS, Shin HJ, Park CK, Kwon YS, Kim YI, Lim SC, Kim YC. Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer. Thorac Cancer. 2014 Nov;5(6):525-9. doi: 10.1111/1759-7714.12123. Epub 2014 Oct 23."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Belotaxel Plus Belloxa","description":"Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"33"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"31"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Belotaxel Plus Belloxa","description":"Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"33"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.0","spread":"9.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"30"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Korean","categories":[{"measurements":[{"groupId":"BG000","value":"33"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Korea, Republic of","categories":[{"measurements":[{"groupId":"BG000","value":"33"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Response Rate","description":"RECIST version 1.1","populationDescription":"Intention to treat population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"6th week","groups":[{"id":"OG000","title":"Belotaxel Plus Belloxa","description":"Belotaxel 60 mg/m2 3 weekly (day 1) plus Belloxa 70 mg/m2 3 weekly (day 2)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"2 years","groups":[{"id":"OG000","title":"Belotaxel Plus Belloxa","description":"Belotaxel 60 mg/m2 3 weekly (day 1) plus Belloxa 70 mg/m2 3 weekly (day 2)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"2.8","upperLimit":"4.5"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"2 years","groups":[{"id":"OG000","title":"Belotaxel Plus Belloxa","description":"Belotaxel 60 mg/m2 3 weekly (day 1) plus Belloxa 70 mg/m2 3 weekly (day 2)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"8.2","upperLimit":"13.6"}]}]}]},{"type":"SECONDARY","title":"Neutropenia Grade 3-4","description":"Toxicity (CECAE ver 4.0) and Safety","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"2 years","groups":[{"id":"OG000","title":"Belotaxel Plus Belloxa","description":"Belotaxel 60 mg/m2 3 weekly (day 1) plus Belloxa 70 mg/m2 3 weekly (day 2)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"4 months","eventGroups":[{"id":"EG000","title":"Belotaxel Plus Belloxa","description":"Belotaxel 60 mg/m2 3 weekly (day 1) plus Belloxa 70 mg/m2 3 weekly (day 2)","seriousNumAffected":10,"seriousNumAtRisk":33,"otherNumAffected":33,"otherNumAtRisk":33}],"seriousEvents":[{"term":"Febrile Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":33}]},{"term":"Thromboembolism","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":33}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":33}]}],"otherEvents":[{"term":"Anorexia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":33}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":33}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Young-Chul Kim","organization":"Chonnam National University Hwasun Hospital","email":"kyc0923@jnu.ac.kr","phone":"82-61-379-7614"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077143","term":"Docetaxel"},{"id":"D000077150","term":"Oxaliplatin"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}